Press Releases

Date Title and Summary Additional Formats
Toggle Summary Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass. , July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the
View HTML
Toggle Summary Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass. , June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $7.75 per share. Proceeds to Minerva from the offering, before deducting underwriting discounts and commissions and other offering expenses,
View HTML
Toggle Summary Minerva Neurosciences, Inc. to Offer Common Shares
WALTHAM, Mass. , June 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 5,000,000 shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the proposed offering are to be sold by Minerva.
View HTML
Toggle Summary Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia
WALTHAM, Mass. , June 22, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the successful completion of a bridging trial to select an improved, gastric-resistant (GR) formulation of MIN-101.
View HTML
Toggle Summary Minerva Announces Amended Agreement for MIN-202 in Insomnia
WALTHAM, Mass. , May 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it has entered into a binding term sheet to amend its co-development and license agreement with Janssen Pharmaceutica NV (Janssen) related to MIN-202 (JNJ 42827922)
View HTML
Toggle Summary Minerva Neurosciences to Present at Jefferies 2017 Healthcare Conference on June 6, 2017 View HTML
Toggle Summary Minerva Provides Update on Phase 3 Design and Development Strategy for MIN-101 View HTML
Toggle Summary Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA View HTML
Toggle Summary Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates View HTML
Toggle Summary Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
Management to host conference call
View HTML